| INTRODUCTION
Intracranial gliomas represent approximately 30% to 35% of primary brain tumours in dogs with an increased incidence reported in specific breeds including Boxers, Bulldogs, Boston Terriers, Mastiffs and Jack Russell Terriers.
1,2 Data relating to treatment outcomes in dogs are limited, however, similar to human tumour counterparts, prognosis following standard therapy (surgery, radiation therapy and chemotherapy) is poor. 3, 4 Major advances in molecular genetic phenotyping of gliomas have been made in human neurooncology allowing a more rational approach to development of novel tumour marker and pathway-based targeted therapies. 5, 6 Similar approaches are ongoing for brain tumours in dogs and may provide a translational platform for therapeutic development beneficial to both species. [7] [8] [9] [10] [11] [12] [13] [14] The cAMP response element-binding protein (CREB) family member, activating transcription factor 5 (ATF5) is an important regulator of normal central nervous system (CNS) development, and appears to be important for gliomagenesis and tumour cell survival across a range of tumour grades in humans and rodent models. Consistent with these roles, ATF5 has been shown to be expressed in rodent neural and glial progenitor cells [15] [16] [17] and human glioma-associated stem cells, 18, 19 and is also highly expressed in mouse, rat and human gliomas. 18, [20] [21] [22] [23] [24] Based on these data, abrogation of ATF5 function in ATF5-expressing neoplastic cells has been proposed as an interventional strategy to treat gliomas either as a monotherapy or adjunctively in synergism with standard therapeutic modalities.
Although ATF5 expression in the mature CNS is reportedly limited to reactive astrocytes 16, 20 and progenitor cells, [15] [16] [17] preferential targeting of neoplastic cells, even within this limited population of ATF5-expressing normal cells, is important to ensure a high therapeutic index for any ATF5-targeted therapies in the clinical setting. In vitro, targeting of ATF5 using siRNA-ATF5 or dominant negative ATF5 (d/n-ATF5) constructs results in normal differentiation of neural progenitors in rodents, [15] [16] [17] and has no apparent deleterious effects on non-neoplastic, activated astrocytes. 20 In contrast, human, mouse, and rat glioma cells in vitro undergo apoptosis when subjected to ATF5 expression knock down or functional abrogation. 20, 22, 25 Similarly, in vivo investigations utilizing different methods of ATF5 interference in a variety of rodent glioma models have demonstrated selective regression or eradication of tumours via promotion of massive apoptosis, while maintaining integrity of surrounding normal brain. 21, 22, 25 Truncated, but fully active dominant negative ATF5 peptides have been developed that are fused to a cell-penetrating domain permitting passage through the blood-brain barrier into intact cells.
These peptides can be delivered systemically and provide a potential means to utilize an ATF5-targeted approach in the clinical setting. 22, 25 To validate the use of similar ATF5-targeted strategies in dogs with spontaneous gliomas, ATF5 protein expression in canine spontaneous glioma tumour samples was assessed using western blotting and immunohistochemistry, and sensitivity of canine glioma cell lines to an ATF5 dominant-negative peptide was assessed in vitro. We report that ATF5 is overexpressed in canine gliomas, and that similar to human tumour cell lines, in vitro treatment with a synthetic cell-penetrating dominant-negative ATF5 peptide results in decreased canine glioma cell viability. containing both white and grey matter were similarly collected at necropsy.
| MATERIALS AND METHODS

| Sample collection
| Cell culture
Three canine glioma cell lines (J3TBg, SDT3G and G06A) were assayed by western blotting and the J3TBg and SDT3G cell lines were used for cell viability assays. The J3Tbg cell line was derived from a grade III astrocytoma. 27 SDT3G and G06A cell lines were derived from glioblastoma samples G3 and G6, respectively. All cell lines were grown in high glucose DMEM with 1.5% or 10% fetal bovine serum (FBS) as previously described. 7 
| Western immunoblot
Proteins were extracted from archived frozen tissue and cell lines using RIPA buffer (Thermo Fisher Scientific, Waltham, Massachusetts)
and quantified using a Pierce BCA Protein Assay (Thermo Fisher Scientific). Western blotting was performed as previously described and 20 μg of total protein were loaded for each sample. 
| Immunohistochemistry
Antigen retrieval and immunofluorescence staining to define cellular localization of ATF5 expression was done using 4 formalin-fixed, paraffin-embedded dog tumour samples (2 anaplastic oligodendrogliomas and 2 glioblastomas) also containing areas of normal brain, and methodology as previously described 19 with minor changes. Anti- Immunofluorescence was subjectively assessed for localization of ATF5 as nuclear, cytoplasmic or membranous. 
Positive immunostaining for ATF5 was seen in all tumour samples consistent with western blotting data, and was localized in both nuclear and cytoplasmic compartments. Membranous expression was not observed (Figure 2 ). Immunostaining in peritumoural normal brain was minimal compared with tumour tissue (Figure 3 ).
| Cell viability assays
Exposure of canine glioma cell lines J3TBg and SDT3G to the CP-d/n ATF5 peptide for 5 days resulted in a concentration-dependent decrease in cell viability at micromolar concentrations. Similar biological effects were seen using low serum media conditions (1.5% FBS, 
| DISCUSSION
The current study suggests that overexpression of ATF5 previously reported in human and rodent gliomas is recapitulated in spontaneous dog gliomas, and that investigated ATF5 antibody and therapeutic peptide previously described for use in rodents and humans have cross species reactivity and activity in dogs.
The pattern of ATF5 immunostaining seen in dog gliomas in this study ( Figure 2 ) resembles that seen in human gliomas and other human tumours where ATF5 protein is increased, and is consistent with ATF5's role as a nuclear targeted transcription factor. 20, 24, 28 While ATF5 is consistently expressed in the nucleus, cytoplasmic localization is also reported, [15] [16] [17] 29, 30 and ATF5 has been reported to be an essential pericentriolar material protein also localized in the cytoplasm. 31 Previously reported low level immunohistochemical expression of ATF5 in peritumoural non-neoplastic brain 18, 20, 24 was also seen in the dog samples, although extensive anatomical assessment of ATF5 expression beyond cellular localization was not a specific aim of the current study. Specific assessment of expression and effects of ATF5 abrogation in normal brain-derived and tumourderived progenitor/stem-like cells will be necessary to determine if similarities between dogs and humans also extend to this developmental level. Overexpression of ATF5 has been associated with increased tumour grade in human rectal cancer, 32 and ATF5 levels correlate negatively with survival in human glioblastomas. 18, 23, 33 Controlled survival data for dog glioma patients are not available, however, the highest expression of ATF5 on western blotting was seen in the highest grade tumours, (glioblastoma, Figure 1 
